Please assess the completion status of the following clinical trial:

Trial Title: Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with newly diagnosed AML based on the World Health Organization classification who have persistent disease after their first course treatment with an anthracycline and cytarabine~2. Able to understand and have the ability to provide written informed consent~3. Patients over 18 years of age~4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~5. Left ventricular ejection fraction (LVEF) ≥ 50%~6. Negative urine pregnancy test for all females~7. All subjects must agree to use an effective method of contraception while receiving the study drugs~Exclusion Criteria:~1. Diagnosis of acute promyelocytic leukemia~2. Relapsed AML~3. Prior use of clofarabine~4. Previous allogeneic or autologous hematopoietic cell transplantation~5. Impaired liver function (serum total bilirubin \> 2.0 mg/dL, alanine aminotransferase and aspartate aminotransferase ≥ 4 x the upper limit of normal)~6. Impaired renal function (serum creatinine ≥ 2.0 mg/dL)~7. Uncontrolled or life-threatening infection that is not responding to antimicrobial therapy~8. History of a psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent~9. Concurrent active malignancy; exceptions include patients who have been disease free for 5 years, patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, or patients with another malignancy that is indolent or definitively treated~10. Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory or cardiac disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clofarabine and Cytarabine (Type: EXPERIMENTAL): Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5. Cytarabine at a dose of 1g/m2 daily will then be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.

Based on this trial design, predict the completion outcome and termination type (if applicable).